Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0DDQHT
ADC Name	XYD-9668-198
Synonyms	XYD-9668-198 Click to Show/Hide
Organization	Zhongke Xinyun Biotech (Originator)
Drug Status	Phase 1/2
Antibody Name	Anti-TROP2 antibody	Antibody Info
Antigen Name	Tumor-associated calcium signal transducer 2 (TACSTD2); Programmed cell death 1 ligand 1 (PD-L1)	Antigen Info
Payload Name	Undisclosed
Therapeutic Target	Stimulator of interferon genes protein (STING1)	Target Info
Linker Name	A cleavable linker	Linker Info
Conjugate Type	Undisclosed

The indication landscape of This ADC(2027 Update)

The clinical trial pipeline of This ADC(2027 Update)

Indication

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

New Drug Application

Approved

Unspecific solid tumor

1 Trials

Trial ID
CTR20231203

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	CTR20231203	Phase 1/2	An open, multicenter Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic profile and initial efficacy of XYD-9668-198 antibody coupling agent in patients with advanced solid tumors Click to Show/Hide

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Patients with advanced solid tumors confirmed histologically or cytologically must have received standard treatment, have not responded to standard treatment, or have been intolerant to standard treatment, including, but not limited to, triple-negative breast cancer, cervical cancer, endometrial cancer, ovarian cancer, uroepithelial cancer, pancreatic cancer, esophageal cancer, and non-small cell lung cancer. Triple-negative breast cancer, cervical cancer, ovarian cancer and urothelial carcinoma were included in the dose expansion phase. Click to Show/Hide
Administration Dosage	.
*Related Clinical Trial*
NCT Number	CTR20231203	Clinical Status	Phase 1/2
Clinical Description	An open, multicenter Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic profile and initial efficacy of XYD-9668-198 antibody coupling agent in patients with advanced solid tumors

References

Ref 1	Other clinical trials of XYD-9668-198 antibody-drug conjugate for Injection in Hangzhou - Research on XYD-9668-198 antibody-drug Conjugate in patients with advanced solid tumors